Volvo Cars and HCLTech Collaborate to Drive Engineering Transformation
HCLTech, a leading global technology company, today announced that Volvo Cars has chosen HCLTech as one of its strategic suppliers for engineering services.
Volvo Cars has been at the forefront of automotive innovation for many years and has set out to shape the future of mobility with strong ambitions on sustainable growth, as it seeks to offer clients the freedom to move in a personal, sustainable and safe way.
Drawing on an established relationship in digital and PLM services, this agreement significantly expands HCLTech’s role to cover the delivery of end-to-end engineering solutions at scale. The strategic collaboration will see the company support Volvo Cars’ engineering future ambitions from its automotive Centre of Excellence in Gothenburg, as well as its global offshore and nearshore delivery centers.
“We are proud to broaden our relationship with Volvo Cars at such a pivotal moment in its transformation journey,” said Pankaj Tagra, HCLTech Corporate Vice President, Manufacturing and Allied Industries, Europe. “HCLTech is investing substantially in nextgen automotive engineering. This strategic engagement reflects our commitment to delivering high performance, future-ready engineering solutions that help shape the mobility of tomorrow.”
Tagra added that the partnership cements HCLTech’s position as a strategic engineering partner of choice for global automotive leaders, as more executives recognize the potential of its solutions to help unlock the future of mobility.
About HCLTech
HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2025 totaled $13.8 billion. To learn how we can supercharge progress for you, visit hcltech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612770229/en/
Contacts
For more information, please contact:
Meredith Bucaro, Americas
meredith-bucaro@hcltech.com
Elka Ghudial, EMEA
elka.ghudial@hcltech.com
James Galvin, APAC
james.galvin@hcltech.com
Nitin Shukla, India
nitin-shukla@hcltech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Reply earns Oracle Service Expertise in Artificial Intelligence for the Western Europe region13.6.2025 11:00:00 EEST | Press release
Technology Reply, a company of the Reply Group specialising in the design of solutions based on Oracle technologies, has been presented with the Oracle Service Expertise in Artificial Intelligence for the Western Europe region, further consolidating its position as a key partner for AI projects on Oracle Cloud Infrastructure (OCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613439196/en/ Thanks to this certification, Technology Reply strengthens its role as a technology partner for companies seeking to enhance their enterprise applications, improve user interaction, and accelerate decision-making processes through artificial intelligence and Oracle technologies. The Service Expertise certification is in recognition of Technology Reply’s technical and design capabilities in building solutions based on OCI’s AI services, including the use of pre-trained models, chatbot development, custom model creation, and the adoptio
Lone Star Announces Sale of novobanco to BPCE13.6.2025 10:00:00 EEST | Press release
Nani Holdings S.à. r.l., an affiliate of Lone Star Funds (“Lone Star”), today announced that it has signed a Memorandum of Understanding for the sale of Novo Banco, S.A. (“novobanco” or “the bank”), Portugal’s fourth-largest bank, to BPCE, a leading European banking institution, for a cash consideration payable at closing which values 100% of the share capital at an estimated €6.4 billion as of end 2025. This transaction marks the culmination of a multi-year transformation of novobanco since Lone Star acquired 75% of the bank in 2017. Under Lone Star’s stewardship, in cooperation with other shareholders, novobanco has undergone a comprehensive turn-around, establishing itself as one of the most profitable banks in Europe, with a target return on tangible equity (RoTE) exceeding 20%. The bank has significantly de-risked its balance sheet, reducing non-performing loans to de minimis levels, and has made substantial investments in digital transformation and customer experience. Throughout
xFusion Unveils Breakthrough High-Performance Computing Innovations at ISC 202513.6.2025 06:33:00 EEST | Press release
xFusion International Pte. Ltd (xFusion) showcased its latest advancements in high-performance computing (HPC) and sustainable intelligent computing solutions at the International Supercomputing Conference (ISC) 2025, held from June 10 to 13 in Hamburg, Germany. As a global leader in HPC and computing infrastructure, xFusion highlighted its commitment to empowering industries and institutions with cutting-edge technologies that accelerate innovation and digital transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612879566/en/ Arthur Wang Revolutionizing Computing with Innovative Solutions At the Vendor Roadmap Session on June 12, Arthur Wang, Director of xFusion Computing Solution, delivered a compelling keynote titled "Innovative Computing with xFusion." Arthur emphasized the increasing demand for computing power in the age of AI and intelligent agents, as well as xFusion’s role in addressing these challenges.
Kao Releases the Kao Integrated Report 202513.6.2025 05:00:00 EEST | Press release
Kao Corporation (TOKYO:4452) has published the Kao Integrated Report 2025 on its website, offering shareholders, investors, and all stakeholders with a comprehensive overview of the company’s initiatives and strategic direction. Kao Integrated Report 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609991718/en/ The cover visual represents our “moonshot.” It embodies our commitment to achieving the ambitious goal of a sustainable society for future generations. To achieve its Mid-term Plan “K27,” Kao aims to become a unique presence indispensable to someone in the world and is advancing its Global Sharp Top strategy. In FY2024, Kao exceeded its targets by strengthening Return on Invested Capital (ROIC) management and strategically investing to build stronger, more robust businesses. This report offers an in-depth look at Kao’s progress under K27, highlighting how Kao’s dedicated employees—through the Global Sharp Top s
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom